Equities Analysts Issue Forecasts for AC Immune Q1 Earnings

AC Immune (NASDAQ:ACIU) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of AC Immune in a note issued to investors on Monday, March 16th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Friday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.14 million. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 92.65%.

A number of other equities analysts have also recently issued reports on ACIU. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Jefferies Financial Group reissued a “buy” rating and issued a $7.00 price target on shares of AC Immune in a research note on Friday. Finally, BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of AC Immune in a report on Monday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $9.00.

AC Immune Stock Performance

Shares of NASDAQ:ACIU opened at $3.13 on Tuesday. AC Immune has a one year low of $1.43 and a one year high of $4.00. The stock has a fifty day moving average of $3.14 and a 200-day moving average of $3.04. The company has a market capitalization of $314.28 million, a PE ratio of -3.73 and a beta of 1.64.

Institutional Investors Weigh In On AC Immune

Institutional investors have recently bought and sold shares of the business. EFG International AG purchased a new position in AC Immune during the 4th quarter valued at about $41,000. Marshall Wace LLP purchased a new stake in shares of AC Immune in the fourth quarter worth approximately $586,000. Dimensional Fund Advisors LP lifted its position in shares of AC Immune by 20.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock worth $670,000 after purchasing an additional 36,353 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares during the period. Finally, Susquehanna International Group LLP acquired a new stake in shares of AC Immune during the third quarter worth approximately $63,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.